11,128 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by LMG Wealth Partners LLC

LMG Wealth Partners LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 11,128 shares of the company’s stock, valued at approximately $130,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. State Street Corp increased its position in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the period. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Intellia Therapeutics by 125.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock valued at $1,411,000 after buying an additional 67,276 shares during the period. Patient Square Capital LP acquired a new stake in Intellia Therapeutics during the third quarter worth approximately $2,642,000. Charles Schwab Investment Management Inc. increased its stake in Intellia Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock worth $17,006,000 after acquiring an additional 37,714 shares during the period. Finally, Avanza Fonder AB acquired a new position in Intellia Therapeutics in the 4th quarter valued at $421,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on NTLA. Robert W. Baird decreased their price target on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group cut their price target on shares of Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a report on Tuesday, January 14th. Chardan Capital lifted their price objective on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Morgan Stanley downgraded Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $56.00 to $11.00 in a report on Monday, January 27th. Finally, William Blair reissued a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.71.

Intellia Therapeutics Trading Up 6.5 %

Shares of NTLA stock opened at $12.28 on Thursday. Intellia Therapeutics, Inc. has a 1-year low of $8.96 and a 1-year high of $34.87. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -2.26 and a beta of 1.80. The stock has a 50-day moving average of $11.07 and a 200-day moving average of $16.12.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.